Molecular bases of endometrial cancer: New roles for new actors in the diagnosis and the therapy of the disease

详细信息	查看全文 | 推荐本文 |

• 作者：Marta Llauradó ; ^a ; Anna Ruiz^a ; Blanca Majem^a ; Tugce Ertekin^a ; Eva Colá ; s^a ; Nú ; ria Pedrola^a ; Laura Devis^a ; Marina Rigau^a ; Tamara Sequeiros^a ; Melania Montes^a ; Marta Garcia^a ; Sí ; lvia Cabrera^b ; Antonio Gil-Moreno^b ; Jordi Xercavins^b ; Josep Castellví ; ^c ; Angel Garcia^c ; Santiago Ramó ; n y Cajal^c ; Gema Moreno^d ; Francesc Alameda^e ; Mó ; nica Vá ; zquez-Levin^f ; José ; Palacios^g ; Jaime Prat^h ; Andreas Doll^a ; Xavier Matí ; as-Guiuⁱ ; Miguel Abal^j ; Jaume Reventó ; s^a ; ^{jreventos@ir.vhebron.net}
• 关键词：Endometrial carcinoma ; Molecular genetics ; Treatment ; Target therapy ; Aspirates ; Mice
• 刊名：Molecular and Cellular Endocrinology
• 出版年：2012
• 期刊代码：109_03037207
• 类别：bio
• 出版时间：25 July, 2012
• 卷：358
• 期：2
• 页码：244-255
• 文件大小：694 K

摘要

Endometrial carcinoma (EC) is the most commonly diagnosed gynecologic malignancy in the western world. The majority of these cancers are curable, but a subset about 15-20%of endometrial tumors exhibits an aggressive phenotype.

Based on clinic-pathological and molecular characteristics, EC has been classified into two groups: Type I estrogen-dependent adenocarcinomas, which have a good prognosis and an endometrioid histology, and Type II or non-estrogen-dependent EC associated with poor prognosis and non-endometrioid histology. EC develops as a result of a stepwise accumulation of alterations that seem to be specific of each histological type. However, more knowledge is needed to better understand the differences in the biology and the clinical outcome of EC.

We would like to highlight the need to explore new potential biomarkers of EC as a tool for the detection and monitoring of aggressive endometrial tumors that, at the same time, will allow us to develop novel and more selective molecular targeted therapies against EC.